CG Oncology, Inc. Common stock

CGONNASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
65.02 USD
↘ 3.69 (5.37%)🟢LIVE (AS OF 12:15 PM EDT)
🟢Market: OPEN

CGON is currently priced at $65.02. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation front, CGON trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Oct 5, 2026.

Open?$69.17
High?$69.34
Low?$64.65
Prev. Close?$68.71
Volume?189.3K
Avg. Volume?934.5K
VWAP?$66.01
Rel. Volume?0.20x
Bid / Ask
Bid?$65.27 × 100
Ask?$65.68 × 100
Spread?$0.41
Midpoint?$65.48
Valuation & Ratios
Market Cap?6.1B
Shares Out?88.6M
Float?68.6M
Float %?77.4%
P/E Ratio?N/A
P/B Ratio?5.92
EPS?-$2.53
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
142
Market Cap
6.1B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.cgoncology.com
Listed
2024-01-25
Address
3000 PEGASUS PARK DRIVE
DALLAS, TX 75247
Phone: (949) 409-3700
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
21
Short Sent.?
39
Piotroski F-Score?0/9Weak
Altman Z-Score?64.31Safe
Confidence?52%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?16.40%High
Short Interest?11.3M
Days to Cover?17.0
Free Float68.6M
Avg Daily Volume661.5K
Settlement Date2026-09-15
Financial Health
Current Ratio?22.22Strong
Quick Ratio?22.20Strong
Cash Ratio?0.42Low
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
31
5.92FAIR▾
P/S?
Peers
100
S&P
3
977.92HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-24.3CHEAP▾
EV/Sales?
Peers
100
S&P
3
975.25HIGH▾
Returns & Efficiency
ROE?
S&P
7
-21.8%WEAK▾
ROA?
S&P
3
-20.7%WEAK▾
Cash Flow & Enterprise
FCF?$-179343000
Enterprise Value?$6.1B
Fundamentals ratios updated end of day
MarketsMoversWatchlist